Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation by Lavalle, L et al.
RESEARCH ARTICLE
Phenotype and biochemical heterogeneity in
late onset Fabry disease defined by N215S
mutation
L. Lavalle1☯, A. S. Thomas2‡, B. Beaton1‡, H. Ebrahim1‡, M. Reed1‡, U. Ramaswami1‡,
P. Elliott3‡, A. B. Mehta1‡, D. A. Hughes1☯*
1 Lysosomal Storage Disorders Unit, Department of Haematology, Royal Free Hospital and University
College Medical School, London, United Kingdom, 2 UCL Institute of Cardiovascular Science, Barts Heart
Centre, Barts Health NHS Trust, London, United Kingdom, 3 Haematology Department, St George’s Hospital
NHS Foundation Trust, London, United Kingdom
☯ These authors contributed equally to this work.




Fabry disease (FD) results from X-linked inheritance of a mutation in the GLA gene, encoding
for alpha galactosidase A, and is characterized by heterogeneous clinical manifestations. Two
phenotypes have been described “Classic” and “late onset” which cannot be predicted exclu-
sively by genotype. The latter has been considered an attenuated form of the disease often
affecting a single organ system commonly the heart. Recent studies have demonstrated that
cardiac outcomes are similar in patients with classic and late onset mutations. In this study we
investigate the relationship between clinical heterogeneity and plasma lyso-Gb3 in a large sin-
gle centre cohort of N215S patients and compare this to patients with other mutations.
Methods
In this single-centre, retrospective, cross-sectional study we analysed a cohort of 251 FD
patients: 84 N215S mutation (37 males) and 167 non-N215S mutations (58 males). The
Mainz severity score index (MSSI) was used as an index of overall disease severity. Cardiac
function and morphology were assessed by electrocardiogram and echocardiogram. Left
ventricular mass was calculated using the Devereux formula and the left ventricular mass
index (LVMI) calculated to adjust for height (g/m2.7). The presence of white matter lesions
was assessed by cerebral MRI or computed tomography (CT). GFR was measured by
radio-isotope (chromium-EDTA) method and adjusted for patient height (ml/min/m2.7), and
urinary protein quantification was undertaken by 24 hour urine collection. Plasma globotriao-
sylsphingosine (lyso-Gb3) was analysed prior to ERT in 84 patients.
Results
N215S patients showed later symptom onset (males: p< 0.0001, females: p<0.03), later
development of left ventricular hypertrophy (LVH) (median survival without LVH: 41 (non-
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N215S) vs. 64 (N215S) years, p< 0.0001), later development of proteinuria (median survival
without proteinuria 43 (non-N215S) vs 71 years (N215S), p< 0.0001), later occurrence of
cerebrovascular events (stroke/ Transient Ischaemic Attacks (TIA); median survival without
stroke: 74 years (non-N215S) vs. not reached (N215S), p< 0.02), later decline in renal func-
tion to GFR <60 ml/min/1.73m2 (median survival: 56 (non-N215S) vs. 72 (N215S) years, p<
0.01), and greater overall survival (median survival 81 (N215S) vs. 66 (non-N215S) years,
p< 0.0006). Lyso-Gb3 was found to be less elevated in N215S compared to non-N215S
male and female patients. However, the N215S population eventually reached an overall
severity measured by MSSI comparable to the non-N215S without equivalent elevation of
lyso-Gb3 (means: 6.7 vs. 74.3 nmol/L, p < 0.001). In addition, N215S patients showed
strong correlations between lyso-Gb3 levels and LVMI, GFR, and MSSI. These associations
became stronger when we investigated individuals’ life time exposure to lyso-Gb3 (calcu-
lated as [lyso-Gb3]*age): MSSI (r2 = 0.88, p< 0.0001), LVMI (r2 = 0.59, p< 0.005), and GFR
(r2 = 0.75, p = 0.0001).
Conclusion
These results demonstrate that the N215S mutation results in a late onset phenotype involv-
ing the heart and other organs. Correlations between clinical manifestations and plasma
lyso-Gb3 variations in this group suggest a Fabry-relevant disease mechanism for the het-
erogeneity observed in this group.
Introduction
Fabry disease (OMIM 301500; FD) is an X-linked metabolic disorder caused by mutations in
the GLA gene [1], of which over 900 mutations (HGMD1 July 2017) have been reported.
The disease is characterized by deficient activity of α-Galactosidase A (α-Gal A) [1], and pro-
gressive multisystem deposition of its glycosphingolipid substrates [1, 2], including globotriao-
sylceramide (Gb3) and the deacylated form, globotriaosylsphingosine (lyso-Gb3) [3]. The
accumulation process begins during fetal development [4] occurring in every organ [1], with
particular deposition described in endothelial and smooth vascular muscle cells, leading to
microvascular dysfunction [5]. Mutations of the GLA gene can be classified into three groups
according to the resulting effect on the α-Gal A activity [6]: variants which result in an enzyme
activity below 10% of normal in males (nonsense and certain missense mutations) [7], variants
with residual enzymatic activity in the range of 15–30% (missense and certain splice GLA vari-
ants) [8] and variants which code for enzymes whose residual activity is not significantly
reduced (normally about 35–40% of normal in males), also referred as non-pathogenic vari-
ants [6, 9]. Two phenotypes are distinguished “Classic” and “Later Onset”. The former has tra-
ditionally been associated with males and is characterized by an early onset, usually childhood,
presenting with: periodic pain crisis (acroparesthesias), vascular cutaneous lesions (angiokera-
tomas), corneal and lenticular opacities, perspiration abnormalities, progressive proteinuric
renal insufficiency, cardiac disease and cerebrovascular events. It is usually associated with
mutations which result in very low (<1%) residual enzyme activity. The non-classic phenotype
or later onset form, commonly involves a single organ system (usually cardiac or renal), and is
generally associated with preservation of greater enzyme activity e.g. missense mutations [10].
Heterogeneity in Fabry disease
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This classification cannot be predicted exclusively by GLA variant as some mutations display
both phenotypes [11, 12].
Clinical features of Fabry disease display significant heterogeneity in both men and women
[1, 12]; heterozygous females have variable disease manifestations because of random X chro-
mosome inactivation [10] and can manifest the full spectrum and severity of the disease as
males, though on average a decade later [13]. Furthermore, variability in the clinical expression
of the same mutation within members of a single pedigree and of unrelated pedigrees has been
described [14, 15, 16]. It is possible that, as in other conditions, some of the heterogeneity is
due to different genetic and immunological back ground or environmental profiles [17].
Plasma and urine Gb3 have been used as biomarkers of disease progression and treatment
response [18, 19]. However, changes in Gb3 during the first year of therapy did not predict
renal response [20]. More recently lyso-Gb3 has been proposed to better reflect the differences
in phenotype of Fabry patients [21, 22]. Indeed, plasma lyso-Gb3 has been reported to be of
greatest value in classical males with minimum elevation in females and later onset patients
[23], and particularly higher in male patients with severe mutations, such as frame-shift or
nonsense mutations [24]. As a non-invasive alternative, urinary lyso-Gb3 has also proved to be
useful for diagnostics and has shown close correlation with genotype [25].
The N215Smutation is an A-to-G transition in codon 215 of exon 5, which causes the sub-
stitution of an asparagine by a serine (N215S) [26]. This mutation results in an obliteration of a
functional N-glycosylation consensus site, but the enzyme is expressed at -5%-25% of normal
activity in various tissues and cultured cells from affected patients [27]. In fact, it was first iden-
tified in an Italian patient as an atypical variant, who at age 42 had none of the classical Fabry
manifestations (angiokeratoma, acroparesthesias, corneal or lenticular opacities, hypohidrosis,
or renal insufficiency) but only manifestations confined to the heart [27]. Subsequently the
N215Smutation was found to be common among atypical variants, presenting with either
mild disease manifestations or asymptomatic [27, 28, 29]. Patients characterized in the rela-
tively small study of 26 patients by Oder et al. lacked clinical manifestations commonly indica-
tive of Fabry classical phenotype such as acroparesthesias, cerebrovascular events, chronic
kidney disease (CKD), or angiokeratoma.
Despite the apparently isolated manifestations, cardiac outcomes for N215S patients and
other cardiac variants are similar to that of classic patients [15, 30], and some N215S patients
have shown more severe manifestation. Indeed, Oder et al. reported 3 out of 10 index subjects
were diagnosed by renal glomerular biopsy after developing proteinuria of unknown origin.
Furthermore, even though this mutation is predominantly associated with the later onset car-
diac disease, heterogeneity in the phenotype is observed.
In an attempt to understand if this heterogeneity of severity and clinical manifestations is
related to the Gb3 degradative pathway or other genetic or environmental factors we have
tested the variation against circulating levels of lyso-Gb3 in a large single centre cohort of 87
N215S patients and compared this with other mutations. Our hypothesis therefore being that
variation correlating with lyso-Gb3 implicates a Fabry-related disease mechanism.
Materials and methods
The study received ethical approval by the Royal Free Hospital Ethics Committee and patients
gave written, informed consent.
Data collection
Retrospective case notes review was undertaken for all patients. Data was collected from base-
line assessments regarding the route to diagnosis (family screening or index case), presenting
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symptom, baseline symptoms and baseline organ function. Screening of high risk populations,
specifically cardiology clinics, was carried out. Family trees were constructed to determine the
number of affected family members identified in each pedigree.
Decision making regarding the initiation of enzyme replacement therapy was undertaken
according to national guidelines current at the time of baseline assessment.
Follow up data was collected regarding critical organ complications including: death,
stroke, pacemaker/ implantable cardiac defibrillator (ICD) insertion and development of renal
impairment or end stage renal failure (ESRF).
Baseline assessments of organ function
Baseline assessment for the purposes of this study was defined as the date of initial comprehen-
sive assessment of disease status undertaken at a specialist centre. Prior to the mid-1990s, few
UK patients had a comprehensive assessment of their disease status (e.g. cardiac, renal and
neurological function) and therefore in patients diagnosed prior to 1999 there is a lapse in
time between date of diagnosis and baseline assessment. All baseline assessments were per-
formed prior to initiation of Enzyme Replacement Therapy (ERT). A cross-sectional analysis
of organ involvement at the time of baseline assessment was performed. This approach was
taken so that this was not influenced by any effects of ERT on either organ manifestations or
circulating lyso-Gb3 levels.
Cardiac function and morphology were assessed by electrocardiogram (ECG), and echocar-
diogram. Left ventricular mass was calculated using the Devereux formula [31] and the left
ventricular mass index (LVMI) calculated to adjust for height (g/m2.7). Increased LVMI was
defined as48 g/m2.7 in females and50 g/m2.7 in males. For assessment of proportion of
patients with LVH both ECG and echocardiograms were considered, however, for Kaplan-
Meyer analysis only LVMI by echocardiogram was included. Arrhythmia encompassed Wolf-
Parkinson-White syndrome, supraventricular tachycardia, atrial fibrillation, ventricular fibril-
lation, non-sustained ventricular tachycardia, ventricular tachycardia and paroxysmal atrial
fibrillation. Conduction abnormalities included long QT, short PR, and conduction blocks.
Quantification of urinary protein was undertaken by 24 hour urine collection and glomeru-
lar filtration was measured by radio-isotope (chromium-EDTA) method, adjusted for patient
height (ml/min/m2). CKD was staged according to the Renal Association, UK.
The presence of white matter lesions (WML) was assessed by cerebral MRI or computed
tomography (CT), and all images were reviewed by a neuroradiologist.
Calculation of severity scores
Disease severity scores at baseline were calculated utilising the Mainz severity score index
(MSSI) [32]. As severity increases with age, the baseline overall severity score was an age
adjusted score, calculated by subtracting the calculated score from the predicted score for the
patient’s age, as previously published [33].
We classified patients according to clinical severity, based on the MSSI, into “mild”
(MSSI < 20), “moderate” (MSSI 20–40) and “severe” (MSSI > 40) phenotypes.
Measurement of plasma enzyme activity and mutational analysis
All patients had mutational analysis performed and measurements of, either plasma or leuko-
cyte, enzyme activity [34]. For mutational analysis, initial screening for abnormal exons was
performed on leucocyte DNA by high resolution melt curve analysis. Sanger sequencing was
then performed on abnormal exons to identify the causative mutation.
Heterogeneity in Fabry disease
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Measurement of plasma Globotriaosylsphingosine
Samples for analysis of plasma lyso-Gb3 concentration were available for 169 patients (84
prior to commencement of ERT and 85 during ERT).
Plasma lyso-Gb3 levels were measured at the laboratory of Genetic Metabolic Diseases in
the Academic Medical Centre using an (adjusted) tandem mass spectrometry method with
glycine labelled as an internal standard [35].
In order to calculate life time exposure to lyso-Gb3 ([Lyso-Gb3]age) we multiplied a
patient’s lyso-Gb3 level by age at time of diagnosis.
Statistical analysis
Statistical analysis was performed using Excel 2010, Microsoft1 and GraphPad Prism version
5 (GraphPad1). For comparisons between two groups, t-tests were used for normally distrib-
uted data, Mann-Whitney U test if the data was not normally distributed and Fisher’s exact
test to compare between proportions. Retrospectively collected data on events (development
of stroke or transient ischaemic attack (TIA), development of stage III CKD (GFR <60ml/
min/1.73m2), presence of WML, development of proteinuria, development of left ventricular
mass indexed to height (LVMI) 50g/m2.7 in males and 48g/ m2.7 in females, and death)
were used to assess the event free survival by using Kaplan-Meyer curves. Survival time was
defined as the interval described in years between birth and event or last follow-up. A p value
<0.05 was considered significant.
Results
Demographics
The cohort comprised 251 patients (95 male (37.8%) (current age: 15–87, median age 52
years), 156 female (62.2%) (current age: 12–90, median age 47 years)) from 96 different family
pedigrees. Population characteristics are given in Table 1. Fifty-nine different mutations were
identified. 67 patients (43 male, 24 female) were index cases and 184 (52 male, 132 female)
were diagnosed on family screening. Eighty-four patients (33.5%) from 29 pedigrees (30.2%)
had the N215Smutation. Most of these patients have been diagnosed in the 21st Century, with
only 3/84 patients (3.6%) of patients diagnosed prior to 2000 having the N215Smutation com-
pared to 81/84 (96.4%) diagnosed 2000 onwards. 22/43 (51.2%) of index males had the N215S
mutation.
Index case presenting symptoms
N215S index males had a significantly older age of symptom onset compared to those with
non-N215S mutations (median age 57 years vs. 9 years, p<0.0001, Fig 1B), as well as age of
diagnosis (median age 58 years vs. 23 years, p<0.0001; Fig 1A).
First signs and symptoms among index cases included: (1) Cardiac: shortness of breath, pal-
pitations, syncope, abnormal ECG, chest pain, fatigue, murmur, cardiomegaly found on
screening, and cardiac arrest. (2) Renal: proteinuric CKD, haematuria, hypertension, renal fail-
ure, proteinuria during pregnancy, and persistent proteinuria post pregnancy. (3) Dermato-
logical: rash and angiokeratomas. (4) Neurological: pain, migraine, and TIA. (5) Strokes:
single episodes and recurrent strokes. (6) Ophthalmological: sore eye, cornea verticillata, and
eye deposits. (7) Gastrointestinal: irritable bowel syndrome (IBS) (Table 1).
The N215Smutation presented predominately with later onset cardiac manifestations in
males. In 18 out of 22 index N215S patients the initial disease manifestations were cardiac,
either symptomatic (syncopal episodes, palpitations or chest pain) or the incidental finding of
Heterogeneity in Fabry disease
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Table 1. Demographics.
Parameters N215S non-N215S
Overall N = 84 N = 167
Males Females Males Females
N (%) 37 (44.1) 47 (55.9) 58 (34.7) 109 (65.3)
Age (years) at diagnosis
Mean (SD) 51.1 (19.2) 38.3 (16.1) 26.1 (16.4) 34.5 (16.8)
Median (range) 58 (13–74) 36 (11–78) 23 (1–65) 34 (4–75)
Age (years) of symptoms onset
N (missing) 241 (0) 142 (0) 533 (0) 594 (4)
Mean (SD) 51.7 (14.5) 36.8 (21.6) 13.2 (12.6) 25.1 (16.4)
Median (range) 57 (7–73) 28.5 (13–66) 9 (1–57) 18 (5–61)
Index cases, n (%) 22 (59.5) 2 (4.3) 21 (36.8) 22 (20.2)
First signs & symptoms:
Cardiac, n (%) 18 (81.8) 1 (50) 3 (14.3) 3 (13.6)
Renal, n (%) 2 (9.1) 1 (50) 1 (4.8) 1 (4.6)
Dermatological, n (%) - - 2 (9.5) 3 (13.6)
Neurological, n (%) - - 15 (71.4) 6 (27.3)
Stroke, n (%) - - - 4 (18.2)
Ophthalmological, n (%) - - - 4 (18.2)
Gastrointestinal, n (%) 2 (9.1) - - 1 (4.6)
Leukocyte α-Gal A
(normal range = 33–134 nmol/mg protein/hr)
N (missing) 15 (22) 14 (33) 31 (26) 47 (62)
Median (range) 7.0 (2.1–14) 49 (7–73) 2.3 (0.1–8.3) 33 (7.9–88)
Plasma α-Gal A
(normal range = 4–21.9 nmol/ml/hr)
N (missing) 36 (1) 46 (1) 49 (8) 102 (7)
Median (range) 0.2 (0–0.6) 4 (1.9–7.4) 0.1 (0–1.1) 3.7 (0.4–12.6)
Overall severity (current),
N (missing) 35 (2) 43 (4) 49 (8) 94 (15)
Mild (MSSI < 20), n (%) 13 (37.1) 41 (95.4) 8 (16.3) 65 (69.2)
Moderate (MSSI = 20–40), n (%) 21 (60) 2 (4.7) 35 (71.4) 27 (28.7)
Severe (MSSI 40), n (%) 1 (2.9) - 6 (12.3) 2 (2.1)
Overall severity (baseline),
N (missing) 37 (0) 46 (1) 53 (5) 103 (6)
Mild (MSSI < 20), n (%) 19 (51.4) 42 (91.3) 6 (11.3) 73 (70.9)
Moderate (MSSI = 20–40), n (%) 17 (46) 4 (8.7) 45 (84.9) 29 (28.2)
Severe (MSSI 40), n (%) 1 (2.7) - 2 (3.8) 1 (1)
Age adjusted score
N (missing) 37 (0) 46 (1) 55 (2) 105 (4)
Mean (SD) -5 (5.7) -2.1 (5.4) 7.6 (0.9) 4.8 (7.1)
Median (range) -6 (-13.9–6.5) -2.5 (-11.7–9.2) 8.6 (-9.5–21.6) 3.7 (-7.6–20.9)
Currently on ERT, n (%) 33 (89.2) 11 (23.4) 56 (98.2) 62 (56.9)
Agalsidase alfa, n (%) 30 (90.9) 10 (90.9) 50 (87.7) 58 (93.6)
Agalsidase beta, n (%) 2 (6.1) 1 (9.1) 6 (10.5) 4 (6.5)
α-Gal A = alpha-galactosidase A; ERT = enzyme replacement therapy; Patients were stratified according to clinical severity, based on the Mainz Severity Score Index
(MSSI), into “mild” (MSSI < 20), “moderate” (MSSI 20–40) and severe (MSSI > 40) phenotypes. Number of patients with no symptoms prior to diagnosis: 1. N = 13, 2.
N = 33, 3.N = 4, 4. N = 46.
https://doi.org/10.1371/journal.pone.0193550.t001
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LVH during pre-operative assessments or insurance medicals (7 patients) (Table 1). In two
N215S index males the initial symptoms were of IBS, with the diagnosis being made following
subsequent development of cardiac manifestations. Two N215Smale index cases presented at
a significantly younger age (25 and 38 years) with ESRF. In contrast, acroparesthesia and/or
angiokeratoma were the commonest initial symptoms in non-N215S index males, occurring in
17 out of 21 patients (81%, p<0.0001). In three the initial symptoms were cardiac (onset aged
32, 44, and 50 years) and one proteinuria (initially noted age 29).
Both groups attained similar overall severity scores, but at different ages. Mild N215S
patients (MSSI < 20) were significantly older compared to non-N215S (mean age: 36.6, n = 19
vs. 29.5 yeas, n = 6, p = 0.005). Moderate (MSSI = 20–40) and severe (MSSI 40) patients were
also older in the N215S group (63.7 years (n = 17) vs. 35.6 years (n = 45) p< 0.0001 and 71
(n = 1) vs. 29.7 years (n = 2), p = ns, respectively).
Females accounted for over 50% of index cases in the non-N215S population compared
with only two (8.3%) in N215S patients (p = 0.0004), one presenting with proteinuria in preg-
nancy aged 25 years and the other with cardiac hypertrophy aged 68. Whilst non-N215S
women were diagnosed, on average, 8.4 years after males (means: 34.5 vs. 26.1 years,
p = 0.002), N215Swomen were diagnosed 12.8 years before males with the same mutation
(means: 38.3 vs. 51.1 years, p< 0.002) due to family screening of younger generations. Only
non-N215S females reached severe overall MSSI severity scores (MSSI 40), both at baseline
and during follow-up (Table 1).
Whilst similar proportions of male patients were on ERT (N215S: 33/37, 89.2% vs. non-
N215S: 56/58, 96.6%), only 11/47, 23.4% of N215S females were on treatment compared to
62/109, 56.9% in the non-N215S group (p = 0.0001). Indeed, N215S females received the least
proportion of any concomitant medication when compared to the rest of the cohort (Table 2).
Follow up and survival
Baseline assessments were performed on a total of 95 males (index and screening) at a mean age
of 26.1 years in non-N215S males (n = 58) and 51.1 years in N215S (n = 37), p<0.0001. The
mean age at latest follow up for non-N215S males was 44.1 years (range 20–65, n = 51) and 56.3
years for N215Smales (range 18–82, n = 35). There were 10 deaths amongst male FD patients, 7
in non-N215S males (3 cardiac related, 3 stroke and 1 malignancy; mean age 48.3 years) and 3
N215Smales (all cardiac; mean age 75.7 years). Only 2 females passed away during the follow
up, one carrying the G361Rmutation (cardiac death, aged 77) and the other harboured a H46Y
Fig 1. (A) Age at diagnosis for males N215S (n = 37), males non-N215S (n = 58) and females N215S (n = 47), females
non-N215S (n = 109). (B) Age at symptom onset for males N215S (n = 24), males non-N215S (n = 53) and females
N215S (n = 14), females non-N215S (n = 59); ns = not significant.
https://doi.org/10.1371/journal.pone.0193550.g001
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Table 2.
Parameters N215S non-N215S
Overall N = 84 N = 167
Males Females Males Females
N (%) 37 (44.1) 47 (55.9) 58 (34.7) 109 (65.3)
Risk factors for cardiovascular disease
Smoking history, n (%) 15 (40.5) 8 (17) 7 (12.1) 19 (17.4)
Obesity (35 km/m2), n (%) 3 (8.1) 1 (2.1) - 5 (4.6)
Diabetes mellitus, n (%) 5 (13.5) 3 (6.4) 1 (1.7) 3 (2.8)
Fabry related symptoms
General
Hypertension, n (%) 13 (35.1) 7 (14.9) 8 (13.8) 19 (17.4)
Tortuous vessels, n (%) 3 (8.1) 2 (4.3) 14 (24.1) 15 (13.8)
Acroparestesia, n (%) 8 (21.6) 7 (14.9) 47 (81) 51 (46.8)
Angiokeratoma, n (%) 9 (24.3) 5 (10.6) 44 (75.9) 33 (30.3)
CNS
Brain imaging changes (MRI / CT), n (%) 19 (51.4) 13 (27.7) 29 (50) 40 (36.7)
Cerebrovascular event, n (%) 3 (8.1) 1 (2.1) 11 (19) 16 (14.7)
Cardiac
LVH, n (%) 17 (46) 4 (8.5) 22 (37.9) 24 (22)
Arrhythmia, n (%) 11 (29.7) 0 (0) 3 (5.2) 13 (11.9)
Conduction abnormalities, n (%) 11 (29.7) 8 (17) 10 (17.2) 17 (15.6)
LVMI, n (missing) 31 (6) 40 (7) 49 (9) 82 (27)
Mean (SD) 58.2 (22.7) 33 (16.3) 53.1 (20.2) 42.7 (15.9)
Median (range) 50.6 (27.6–105.3) 29.3 (9.8–94.4) 48.6 (23.2–129) 38 (18.2–94.6)
Remodelling, n (missing) 25 (12) 31 (16) 35 (26) 68 (41)
Normal1, n (%) 7 (28) 24 (77.4) 14 (40) 43 (63.2)
Concentric2, n (%) 5 (20) 4 (12.9) 9 (25.7) 7 (10.3)
Concentric hypertrophy3, n (%) 11 (44) 3 (9.7) 10 (28.6) 16 (23.5)
Eccentric hypertrophy4, n (%) 2 (8) - 2 (5.7) 2 (2.9)
Permanent pacemaker, n (%) 7 (18.9) 1 (2.1) 2 (3.5) 1 (0.9)
Implantable cardioverter-defibrillator, n (%) 6 (16.2) 0 (0) 3 (5.2) 2 (1.8)
Renal
Proteinuria, n (%) 12 (32.4) 3 (6.4) 23 (39.7) 21 (19.3)
CKD stages, n (missing) 37 (0) 41 (6) 49 (9) 99 (10)
1(> 90 mL/min/1.73m2) 16 27 25 57
2(60–89 mL/min/1.73m2) 13 13 16 32
3A(45–59 mL/min/1.73m2) 4 0 4 5
3B(30–44 mL/min/1.73m2) 1 1 3 4
4 (>15–29 mL/min/1.73m2) 1 - 1 1
5(<15 mL/min/1.73m2 or on dialysis) 2 - - -
Concomitant medication
ARB/ACE therapy any time, n (%) 17 (46) 6 (12.8) 27 (46.6) 33 (30.3)
ß blocker therapy any time, n (%) 12 (32.4) 3 (6.4) 6 (10.4) 15 (13.8)
Antiplatelet therapy any time, n (%) 19 (51.4) 9 (19.2) 22 (37.9) 32 (29.4)
Anticoagulant therapy any time, n (%) 4 (10.8) 0 (0) 3 (5.2) 8 (7.3)
Statins therapy any time, n (%) 20 (54.1) 8 (17) 15 (25.9) 25 (22.9)
Anticoagulant therapy includes warfarin; antiplatelet therapy includes aspirin, dipyridamole, and clopidogrel; Brain imaging changes were assessed through magnetic
resonance imagining (MRI) and computed tomography (CT), they include white matter lesions (WML), infarcts, vessels dissection and tortuosity. CNS = central
nervous system; LVH = left ventricular hypertrophy, assessed through echocardiogram (>48 g/m2.7 in females and >50 g/m2.7 in males); CKD = chronic kidney disease;
LVMI = left ventricular mass indexed to height. 1. Normal LVMI + RWT 42%. 2. Normal LVMI + RWT 42%. 3. Increased LVMI + RWT 42%. 4. Increased
LVMI + RWT42%. [36]. Proteinuria: >150 g/24hs. Arrhythmia included Wolf-Parkinson-White syndrome, supraventricular tachycardia, atrial fibrillation,
ventricular fibrillation, non-sustained ventricular tachycardia, ventricular tachycardia and paroxysmal atrial fibrillation. Conduction abnormalities included long QT,
short PR and conduction blocks.
https://doi.org/10.1371/journal.pone.0193550.t002
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mutation (she had a stroke at 65 years old). Overall, survival was significantly greater in N215S
males than non-N215S males (Fig 2F, median survival 81 vs. 66 years, p< 0.0006). However, we
did not find significant differences in overall survival amongst females (Fig 2L).
Cardiac manifestations (Table 2)
Cardiac evaluation at baseline included ECG and echocardiogram (LVH defined as an
LVMI> 48 g/m2.7 in females and> 50 g/m2.7 in males). 29 patients were missing echocardio-
gram at baseline (9 males, 20 females).
24 (28.6%) N215S patients (20 males, 4 females) and 49 (29.3%) non-N215S (23 males, 26
females) had LVH on echocardiogram. 1 male non-N215S had LVH by voltage criteria (LVMI
data missing). Furthermore, 2 male N215S patients and 3 non-N215S (1 male, 2 females) were
found to have LVH at baseline but their LVMI data was not available.
Of the 6 patients one presented with ESRF at age 25, two teenagers had conduction ab-
normalities on ECG and showed no symptoms, 1 required an ICD after developing a Non-
Sustained Ventricular Tachycardia (NSVT) with pre-syncope, and 1 had acroparesthesia, gas-
trointestinal symptoms and a few WML on brain MRI. Only 4 N215S females had developed
LVH at baseline and they were aged 68, 72, 78 and 42 years old. Cardiac hypertrophy was pres-
ent in all except for 8 male non-N215S patients (R301Q (aged 14), A143T (aged 1), P205T (aged
3), exon 1 deletion (aged 13), c.700_702 del GAT deletion (aged 27), G361R (aged 11), L372P
(aged 19), and R49L (aged 28)). The patients with c.700_702 del GAT deletion, L372P, and R49L
have subsequently developed conduction abnormalities. However, only 30/109 of non-N215S
female patients exhibited cardiac hypertrophy, at a mean age of 43.3 (range 10–75) years old.
Most males exhibited concentric hypertrophy with no difference between mutation groups
(Table 2). On echocardiogram, there were no differences in LVMI magnitude between muta-
tion groups (Fig 3A). However, Kaplan-Meier survival analysis demonstrated that the develop-
ment of a LVMI over 50g/m2.7 in males occurred at a younger age for the non-N215S
population (median survival: 41 vs. 64 years, p< 0.0001, Fig 2E). Females described a similar
Fig 2. Kaplan-Meier survival analyses. A-F Males; G-L Females. (A, G) Stroke or Transient ischaemic attack (TIA),
(B, H) stage III chronic kidney disease (GFR<60ml/min/1.73m2), (C, I) White matter lesions (WML), (D, J)
Proteinuria (defined as a protein excretion of over 150g/24hs), (E, K) Left ventricular mass by echocardiogram indexed
to height (LVMI) 50g/m2.7 in males and 48g/ m2.7 in females, and (F, L) Overall survival, during follow-up, by
gender and mutation status. The small vertical lines represent censored data (follow-up until the vertical line without
development of an event).
https://doi.org/10.1371/journal.pone.0193550.g002
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disposition (50 vs. 72 years, p = 0.003) (Fig 2K). 13 (29.7%) N215Smen have had ICD or per-
manent pacemakers (PPM) inserted for arrhythmias at a median age of 69 years (range 51–
79), whereas only 5 (8.8%) non-N215S men required one at a median age of 56 years (range
47–59, Table 2). Only 4 women required an ICD or PPM inserted, 1 N215S aged 63 years old
and 3 non-N215S (aged 60, 64, and 72 years old, Table 2).
As potential contributory factors, 15 (40.5%) N215Smen had smoking history compared to
only 7 (12.1%) classic men. Furthermore, 5 (13.5%) N215Smen had type 2 diabetes compared
to only 1 (1.8%) non-N215S man (Table 2). In the case of females, similar proportions had
smoking history, 6.4% of N215S and 2.8% of non-N215S are diabetic and, of note, 5 non-N215S
patients had a BMI over 35 kg/m2 compared to only 1 N215Swoman (Table 2). Hypertension
was more common in N215Smales (35.1% vs. 13.8%, p<0.03 Table 2), however, in females it
predominated in the non-N215S group (17.4% vs. 14.9%, p = not significant, Table 2).
Beta blockers and statins therapies were more prevalent amongst N215Smales, whereas
angiotensin converting enzyme inhibitors (ACEI) / angiotensin receptor blockers (ARB) were
in non-N215S males. However, for females, all of these four concomitant medications were
more common in the non-N215S population (Table 2).
Renal manifestations
Similar proportions of non-N215S (23/58, 39.7%) and N215S (12/37, 32.4%) males had protein-
uria at baseline (Table 2), but proteinuria developed at an earlier age in non-N215S males
(median survival without development of proteinuria: 43 vs 71 years, p< 0.0001, Fig 2D). Two
N215Smales with proteinuria had diabetes as a potential contributory factor compared to only
1 non-N215S man (Table 2). There were no significant differences in GFR at baseline (Fig 3B),
yet, survival curve analysis revealed that stage II CKD (GFR <60ml/min/1.73m2) is developed
at a significantly younger age in non-N215S males (median survival: 56 vs. 72 years, p< 0.01,
Fig 2B). Progression to stage 5 CKD (GFR <15ml/min/1.73m2) occurred in 2 N215S, all of
whom had marked persistent proteinuria.
The three index males whose initial disease manifestations were renal (2 N215S, 1 non-
N215S) have all had or are awaiting renal transplants. One further non-N215S male patient
was diagnosed on family screening having been symptomatic with acroparesthesia since age 7,
had a GFR of 33 at diagnosis aged 34 and has progressed to end stage renal disease (ESRD).
The other N215S patient was diagnosed on family screening aged 73, but had a history of
Fig 3. Quantification of: (A) Left ventricular mass indexed to height (LVMI) for males N215S (n = 35), males non-
N215S (n = 51) and females N215S (n = 40), females non-N215S (n = 96). (B) Glomerular filtration rate (GFR) for
males N215S (n = 37), males non-N215S (n = 50) and females N215S (n = 41), females non-N215S (n = 99).
https://doi.org/10.1371/journal.pone.0193550.g003
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proteinuria of undefined aetiology first detected at age 56 and a partial nephrectomy many
years previous for tuberculosis.
Amongst females, proteinuria was more common in the non-N215S group (19.3% vs. 6.4%,
p = not significant, Table 2) and Kaplan-Meier analysis demonstrated that it also develops ear-
lier in this group (median survival: 70 years vs. not reached -N215S-, p = 0.03, Fig 2J). Further-
more, there were no differences on GFR at baseline between mutation groups (Fig 3B). Non-
N215S females also developed stage II CKD (GFR<60ml/min/1.73m2) at an earlier age but
this age difference was not significant (70 vs. 72 years old, Fig 2H).
Cerebrovascular manifestations
Cerebrovascular events (stroke/TIA) were more common in non-N215S males (11/58, 19%)
than N215Smales (3/37, 8.1%, p = not significant, Table 2) and occurred at a younger age
(median survival: 61 years vs. not reached -N215S-, p< 0.0001, Fig 2A). In the case of females,
non-N215S had more cerebrovascular events (stroke/TIA) compared to N215S (14.7% vs.
2.1%, p< 0.03, Table 2) and these occurred earlier in life (median survival: 74 years vs. not
reached -N215S-, p< 0.02, Fig 2G). Cerebral WML were found in similar proportions of non-
N215S (29/58, 50%) and N215S (19/37, 51.4%) males but were found at a significantly younger
age in non-N215S (median age 44 vs. 66 years, p<0.0001, Fig 2C). Females described a compa-
rable distribution to males, but with no significant differences amongst mutation groups
(Table 2, Fig 2I).
Relationship of disease manifestations to enzyme activity
Males with the N215Smutation had a significantly lower baseline age-adjusted FOS-MSSI
severity score (mean score -5 vs. +7.6, p<0.0001) and higher leukocyte α-Gal A activity (7.0 vs
2.32 nmol/mg protein/hr, p< 0.0001). They also showed a trend towards higher plasma
enzyme activity compared to non-N215S (0.25 vs. 0.17 nmol/ml/hr, p = 0.07).
Despite the same GLA mutation, there was marked variation in enzyme activity amongst
N215S patients, with enzyme activity correlating weakly with overall disease severity (r2 =
0.136, p<0.03, n = 36, see Fig 4E), but not with LVMI or GFR (Fig 5 and S1 Fig).
α-Gal A activity was higher in females regardless of GLA variant (means: 4.04 vs 0.21 nmol/
mg protein/hr, p< 0.0001) and demonstrated weak correlation with severity in the non-N215S
females only (data not shown).
Fig 4. Correlation analyses: (1) Plasma globotriaosylsphingosine (Lyso-Gb3) and plasma α-Gal A activity for males
N215S (A; n = 13), males non-N215S (B; n = 9), females N215S (C; n = 25), and females non-N215S (D; n = 36). (2) Age
adjusted severity score (AAS) and plasma α-Gal A activity for males N215S (E; n = 36), males non-N215S (F; n = 48),
females N215S (G; n = 45), and females non-N215S (H; n = 98); ns = not significant.
https://doi.org/10.1371/journal.pone.0193550.g004
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Ageing
There were no significant correlations for neither gender, between either leukocyte or plasma
α-Gal A activity and age (S2 Fig). In univariate regression analyses, we found that MSSI signifi-
cantly correlated with age, LVMI and GFR for the N215S patients but not the non-N215S
patients (Table 3).
Plasma Globotriaosylsphingosine (lyso-Gb3)
Lyso-Gb3 was found to be elevated in both N215S and non-N215S compared with historical
controls for both males and females (Table 4). At baseline, in untreated patients, lyso-Gb3 was
higher in the non-N215S males and females than N215Smales and females, respectively.
Female non-N215S lyso-Gb3 was also higher than male or female N215S. Significant heteroge-
neity was noted in lyso-Gb3 levels in all groups (Table 4). On average, lyso-Gb3 was lower in
Fig 5. Correlation analyses: red = females; blue = males: (A) Glomerular filtration rate (GFR) and plasma α-Gal A
activity for males (n = 36) and females (n = 40). (B) GFR and leukocyte α-Gal A activity for males (n = 15) and females
(n = 14). (C) Left ventricular mass indexed to height (LVMI) and plasma α-Gal A activity for males (n = 30) and
females (n = 32). (D) LVMI and leukocyte α-Gal A activity for males (n = 14) and females (n = 14); Data shown for
N215S group (non-N215S: S1 Fig); ns = not significant.
https://doi.org/10.1371/journal.pone.0193550.g005
Table 3. Univariate linear regression analyses.
N215S non-N215S
Univariate analysis Univariate analysis
Lyso-Gb3] r2 = 0.61 p< 0.003 r2 = 0.15 p = ns
MSSI Age r2 = 0.73 p = 0.0002 r2 = 0.13 p = ns
[Lyso-Gb3]age r2 = 0.88 p< 0.0001 r2 = 0. 35 p = ns
[Lyso-Gb3] r2 = 0.52 p< 0.01 r2 = 0.05 p = ns
LVMI Age r2 = 0.40 p< 0.03 r2 = 0.25 p = ns
[Lyso-Gb3]age r2 = 0.59 p< 0.005 r2 = 0.02 p = ns
[Lyso-Gb3] r2 = 0. 33 p< 0.05 r2 < 0.01 p = ns
GFR Age r2 = 0.74 p = 0.0002 r2 = 0.25 p = ns
[Lyso-Gb3]age r2 = 0.75 p = 0.0001 r2 = 0.26 p = ns
MSSI = Mainz Severity Score Index; GFR = Glomerular filtration rate; LVMI = left ventricular mass indexed to height; Lyso-Gb3 = Globotriaosylsphingosine (nmol/L);
Age is expressed in years; [LysoGb3]age = Life exposure to Lyso-Gb3 (nmolyr/L).
https://doi.org/10.1371/journal.pone.0193550.t003
Heterogeneity in Fabry disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0193550 April 5, 2018 12 / 20
the ERT- treated group for both N215S and others compared to their untreated counterparts
(Table 4). Lyso-Gb3 levels were significantly lower in both, treated (5.8 vs 28.9 nmol/L, p<
0.0001) and untreated (4.6 vs. 34.4 nmol/L, p< 0.004) women, regardless of GLA variant (data
not shown).
The N215S population reached an overall severity measured by MSSI comparable to the
non-N215S without equivalent elevation of lyso- Gb3 (Fig 6A–6D).
Older male N215S patients showed higher plasma lyso-Gb3 levels, and exhibited a signifi-
cant association between plasma lyso-Gb3 levels and age (r2 = 0.34, p = 0.04, Fig 7), not seen
for the non-N215S group (S3 Fig). Conversely, lower levels of plasma lyso-Gb3 were found in
the non-N215S patients in the same age group (Fig 7 and S3 Fig) likely due to a survivor effect
or milder forms. Both age and lyso-Gb3 demonstrated a significant correlation with MSSI,
LVMI and GFR (26, 27) (Table 3). However, in univariate linear regression analyses, life time
exposure to lyso-Gb3 levels (calculated as [lyso- Gb3]age) showed a stronger significant posi-
tive correlations with MSSI (r2 = 0.88, p< 0.0001, Fig 6A) and LVMI (r2 = 0.59, p< 0.005, Fig
6I), and a negative one with GFR (r2 = 0.75, p = 0.0001, Fig 6E). No similar correlations were
seen for the non-N215S group (Fig 6B, 6F and 6J).
Table 4. Plasma Lyso-Gb3 quantification.
N215S non-N215S
Overall N = 84 N = 167
Males Females Males Females
N (%) 25 (43.1) 33 (56.9) 39 (23.4) 72 (43.1)
Lyso-Gb3 (nmol/L)
ERT naïve, n (%) 13 (52) 26 (78.8) 9 (23.1) 36 (50)
Mean (SD) 6.7 (2.1) 1.5 (0.9) 74.3 (42.2) 6.8 (4.6)
Median (range) 6.6 (3–9.8) 1.2 (0.4–4.1) 77.4 (20.9–126.9) 6 (0.4–16.5)
During ERT, n (%) 12 (48) 7 (21.2) 30 (76.9) 36 (50)
Mean (SD) 6.3 (3.3) 1.7 (1.5) 37.9 (21.3) 6.7 (3.4)
Median (range) 4.9 (2.6–13.6) 1.1 (0.4–4.9) 33.8 (1.4–113.2) 5.9 (0.4–16.7)
Lyso-Gb3 = Globotriaosylsphingosine. Upper reference limit Lyso-Gb3 = 0.6.
https://doi.org/10.1371/journal.pone.0193550.t004
Fig 6. Correlation analyses: Life time exposure to Lyso-Gb3 ([Lyso-Gb3]age) and: clinical severity, (MSSI) for: (A)
N215Smales (n = 13), (B) non-N215Smales (n = 9), (C) N215S females (n = 26), and (D) non-N215S females (n = 36);
baseline GFR for: (E) N215Smales (n = 13), (F) non-N215Smales (n = 9), (G) N215S females (n = 26), and (H) non-
N215S females (n = 33); LVMI for: (I) N215Smales (n = 12), (J) non-N215S males (n = 9), (K) N215S females (n = 23),
and (L) non-N215S females (n = 34); ns = not significant.
https://doi.org/10.1371/journal.pone.0193550.g006
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In the case of females, we found strong correlations in the N215S group between life time
exposure to lyso-Gb3 and MSSI (r2 = 0.62, p< 0.0001, Fig 6C) and LVMI (r2 = 0.71, p<
0.0001, Fig 6K). However, the non-N215S group showed significant but weak correlations
between life time exposure to lyso-Gb3 and the clinical parameters (MSSI: r2 = 0.42, p<
0.0001, Fig 6D; GRF: r2 = 0.26, p< 0.003, Fig 6H; LVMI: r2 = 0.14, p = 0.03, Fig 6L). No signifi-
cant correlation was noted between plasma lyso-Gb3 and α-Gal A activity, plasma (Fig 4) or
leukocyte (data not shown).
Through this analysis four groups could be distinguished (Fig 8) with distinct relationships
between plasma lyso-Gb3 and plasma enzyme activity, for example males who despite not
showing a significant difference in enzyme activities had different plasma lyso-Gb3 concentra-
tions (means: 6.7 vs. 74.3 nmol/L, p< 0.001, Table 4).
Discussion
The diagnosed prevalence of Fabry disease in the UK has increased substantially over the last
17 years since enzyme replacement therapy became available. This is in part due to raised
awareness and screening of high risk populations, including those found to have unexplained
left ventricular hypertrophy. In this cohort of 251 Fabry patients, 33.5% (84) were found to
have the N215Smutation, which has been described in association with a later onset cardiac
phenotype. Many of the pertinent index cases were referred from cardiology clinics with sub-
sequent diagnosis of family members due to cascade screening, however, some patients pre-
sented in ESRF. At present it is unclear if these pedigrees are distinct or in fact one family as a
result of a founder effect in the UK. Further haplotype analysis is required to confirm this.
We have compared the clinical and biochemical phenotype of this group of patient to the
rest of our cohort who harbour non-N215S mutations in the GLA gene. 59 different mutations
comprised the latter mutation group including deletions, nonsense, and missense mutations
(see S1 Table). N215S patients exhibited a distinct phenotype with significantly later symptom
onset than patients with other mutations. Primary presenting symptoms were cardiac disease
but in some cases renal failure. Males and females displayed higher levels of leukocyte enzyme
Fig 7. N215S correlation analyses: Plasma globotriaosylsphingosine (Lyso-Gb3) and age for males (blue; n = 13)
and females (red; n = 26).
https://doi.org/10.1371/journal.pone.0193550.g007
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activity and lower levels of lyso-Gb3 than non-N215S counterparts. Kaplan-Meyer analysis
revealed that N215S patients develop cardiac hypertrophy and proteinuria at an older age, and
have a greater overall survival. Indeed, N215Smen exceeded the general population life expec-
tancy for over 1.9 years, whereas non-N215S patients was reduced compared to the general
population by 13.1 years [37]. This fact might explain some of the severity found in the N215S
population, who might acquire more disease burden as a result of ageing.
Patients who harboured non-N215S mutations, and in particular those associated with the
classical phenotype, mainly presented with acroparesthesias and angiokeratomas and rarely
cardiac or renal involvement. They also showed an earlier decline in renal function to GFR
<60 ml/min/1.73m2 and an earlier occurrence of cerebrovascular events (stroke/TIA).
There were no differences in LVMI between mutation groups at baseline, however, at the
time of the first assessment the mean age was 25 years older in the N215Smales. N215Smales
reached similar total MSSI scores to that of non-N215S males but, on average, 25.5 years later.
Fig 8. Correlation analyses: Plasma globotriaosylsphingosine (Lyso-Gb3) and plasma α-Gal A activity for males
N215S (blue; n = 13), males non-N215S (orange; n = 9) and females N215S (purple; n = 26), females non-N215S
(green; n = 36).
https://doi.org/10.1371/journal.pone.0193550.g008
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Males with N215S attained similar overall MSSI scores and degree of LVMI to non-N215S
males despite higher residual enzyme activity and lower plasma lyso-Gb3 levels. Liao et al.
reported similar differences in lyso-Gb3 levels between classical and late onset patients, and
similar associations between lyso-Gb3, age and LVMI in their Taiwanese patients carrying the
late onset mutation IVS4 + 919G>A [38]. This may suggest that the heart is more sensitive
than other organs to the effects of lyso-Gb3. With manifestations occurring at lower levels of
lyso-Gb3 in patients with relatively higher leucocyte activities of α-Gal A, lyso-Gb3 may play a
direct role in FD pathogenesis. However, storage alone cannot explain the myocardial remod-
elling found on these patients [39]. Other studies have suggested a pro-proliferative effect of
lyso-Gb3 on smooth muscle cells [3] and a cumulative effect on human podocytes [40], induc-
ing the expression and production of extracellular matrix proteins via TGF-β1 [41] and
Notch1 pathway [42].
Plasma lyso-Gb3 levels appeared to be useful to differentiate between phenotypes in males,
however N215Smales and classical females had similar lyso-Gb3 levels [21, 43]. Despite having
on average only 9% plasma lyso-Gb3 of the non-N215S patients, the plasma lyso-Gb3 levels of
N215Smales showed strong correlations with LVMI, GFR and MSSI. Indeed, these associa-
tions became even stronger when we investigated the individual’s life time exposure to lyso-
Gb3, considering the impact of age.
Our results demonstrated that both age and lyso-Gb3 are major factors influencing N215S
patients’ clinical outcomes and overall disease severity (measured by MSSI), LVMI and GFR. Fur-
thermore, for N215S patients, strong significant correlations of clinical manifestations with life
time exposure to lyso-Gb3 suggests that the cumulative exposure is crucial for the disease progres-
sion. Contrary to previous suggestions [23, 44] this finding supports the utility of lyso-Gb3 and its
age related function in prediction of disease severity in newly diagnosed late onset patients.
None of the correlations between plasma lyso-Gb3 and clinical manifestations found in
N215S patients were evident for non-N215S male patients, consistent with the results of Rom-
bach et al. who investigated these associations in 37 classic male Fabry patients [43]. The
absence of these associations might indicate that above certain levels of lyso-Gb3 in plasma,
higher concentrations are not predictive of the degree of disease severity.
Lower levels of plasma lyso-Gb3 were found in treated patients, implying an effect of ERT;
however, this is a cross-sectional analysis and could reflect a treatment bias therefore further
longitudinal studies are required.
N215S index cases were mostly males, and women were generally diagnosed through cas-
cade screening. Regardless of the mutation, female patients showed higher enzyme activity,
lower lyso-Gb3 levels, and received, proportionally, less treatment (either ERT or concomitant
medications). The ratio of females to males in our N215S cohort is only 1.3 to 1 which is lower
than the expected 2 to 1 for an X-linked disease, and may suggest that N215S female patients
are underdiagnosed due to their mild phenotype. Even in classic men clinical diagnosis of FD
can be difficult due to frequent misinterpretation of early symptoms, and often patients pres-
ent with a long consultation history. Hsu et al. reported that cardiac disease can progress
silently, without showing significant clinical symptoms [45]. Family screening is therefore key
to identifying asymptomatic individuals in order to provide appropriate genetic counselling
prognostication and monitoring.
Strengths and limitations
This is a cross sectional baseline study of a large number of patients with a single mutations
compared to other patients without that mutation in our cohort all investigated and
managed according to a common protocol. We identify a number of strengths including the
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standardised follow up and completeness of the genotyping and clinical data. A further
strength is that we have chosen to compare the N215S cohort of patients to our total cohort of
non-N215S patients including the full range of genotypes some of which are also late onset
thereby avoiding the bias of selecting only mutations previously described to have classic phe-
notype. We report data prior to the initiation of therapy for clinical parameters in all patients
however a limitation is that lyso-Gb3 at baseline was only available for a subset in which the
analysis is performed. Similarly, whilst genotyping was available in all patients a full profile of
enzyme activities was not available for every patient. For the small number of patients diag-
nosed prior to 1999 there is a lapse in time between date of diagnosis and baseline assessment
as patient were not immediately seen in the specialist centre.
We present event and survival follow up for the genotype-defined cohorts as a whole and
have not further analysed by exposure to enzyme replacement therapy which was outside of
the scope of this study. After baseline assessment similar proportions of male N215S patients v
non-N215S patients were in receipt of ERT although a smaller proportion of N215S females
were on treatment reflecting their overall milder phenotype which would have been a con-
founder in any analysis of ERT response. Similarly, the sample size lacked the necessary power
to detect statistically significant differences in ERT effect by genotype.
According to our local protocols, during the majority of the follow up period echocardiog-
raphy with its potential limitations of variability rather than MRI was used to measure LVMI.
Conclusion
Patients with the N215Smutation exhibit a distinct phenotype with later onset but not exclu-
sively cardiac manifestations, with some patients presenting with renal disease. Contrary to
previous reports, lyso-Gb3 is an important parameter in the assessment of patients with the
N215Smutation. In particular severity and clinical manifestations correlated with life time
exposure to plasma lyso-Gb3 in the N215S group and may prove useful in prognostication and
therapeutic decision making.
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S1 Fig. Correlation analyses. (A-D) GFR and: (a) plasma α-Gal A activity for males non-
N215S (A; n = 42) and females non-N215S (B; n = 94), (b) leukocyte α-Gal A activity for non-
N215Smales (C; n = 28) and non-N215S females (D; n = 44). (E-H) LVMI and: (a) plasma α-
Gal A activity for males (E; n = 44) and non-N215S females (F; n = 76), (b) leukocyte α-Gal A
activity for non-N215S males (G; n = 29) and non-N215S females (H; n = 42); ns = not signifi-
cant.
(TIF)
S2 Fig. Correlation analyses. plasma α-Gal A activity and age for males: (A) N215S (n = 36),
(B) non-N215S (n = 49), and females: (C) N215S (n = 46), non-N215S (n = 102); ns = not signif-
icant.
(TIF)
S3 Fig. Correlation analyses. Plasma globotriaosylsphingosine (Lyso-Gb3) and age for Non-
N215Smales (blue; n = 9) and non-N215S females (red; n = 36); ns = not significant.
(TIF)
S1 Table. Mutations included in the non-N215S group.
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